Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation

Last Update: Jan 14, 2025
Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation: a French Multicentric Prospective Observational Study
ClinicalTrials.gov Identifier:
NCT06444087
Novartis Reference Number:CAIN457MFR01
See if you Pre-qualify
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The primary objective of this non-interventional study is to describe the evolution of Hidradenitis suppurativa (HS) symptoms 12 months after secukinumab initiation based on the patients' assessment of pain, oozing, and bad smell. This study is a prospective (primary data), national, descriptive, non-interventional, multicentre study conducted by medical practice and hospital-based dermatologists across different geographical regions in France.

This real-world study does not change the physician-patient relationship or patient management or follow-up. Physicians remain free with their prescriptions and patient follow-up procedures. In fact, secukinumab initiation and all treatment decisions will be made according to routine medical care and independently of study participation.

Recruited patients will be longitudinally followed-up for the duration of the study, up to 24 months (± 3 months) after secukinumab initiation or secukinumab treatment discontinuation before the end of the 24 months of follow-up (early discontinuation).

Condition
Hidradenitis Suppurativa
Overall Status
Recruiting
Number of Participants
177
Start Date
Jun 17, 2024
Completion Date
Mar 30, 2027
Gender

All
Age(s)
18 Years - 99 Years (Adult, Older Adult)

Interventions

Other

secukinumab

This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.

Eligibility Criteria

Inclusion Criteria:

1. Male and female patients ≥ 18 years old,
2. Patients who do not object to participation in the study,
3. Diagnosis of HS clinically confirmed,
4. Initiation of secukinumab treatment for HS in compliance with the summary of product characteristics,
5. The physician's decision to initiate secukinumab has been taken according to his/her own practice and regardless of study participation.

Exclusion Criteria:

1. Patients with any medical or psychological condition which, in the physician's opinion, may prevent participation in the study,
2. Patients participating in a clinical trial.

France

Novartis Investigative Site

Recruiting

Bordeaux Cedex,33075,France

Novartis Investigative Site

Recruiting

Paris,75014,France

Novartis Investigative Site

Recruiting

Lille,59037,France

Novartis Investigative Site

Recruiting

Antony,92160,France

Novartis Investigative Site

Recruiting

Rodez,12000,France

Novartis Investigative Site

Recruiting

Lorient,56322,France

Novartis Investigative Site

Recruiting

Brest,29609,France

Novartis Investigative Site

Recruiting

Rouen,76031,France

Novartis Investigative Site

Recruiting

Lyon,69003,France

Novartis Investigative Site

Recruiting

Calais,62100,France

Novartis Investigative Site

Recruiting

Saint Mande,94160,France

Novartis Investigative Site

Recruiting

Montpellier,34295,France

Novartis Investigative Site

Recruiting

Dijon,21034,France

Novartis Investigative Site

Recruiting

Saint Pierre,97410,France

Novartis Investigative Site

Recruiting

Nantes Cedex 1,44093,France

Novartis Investigative Site

Recruiting

La Rochelle,17019,France

Novartis Investigative Site

Recruiting

Toulouse,31400,France

Novartis Investigative Site

Recruiting

Nice,06000,France

Novartis Investigative Site

Recruiting

Le Mans,72000,France

Novartis Investigative Site

Recruiting

Vannes,56000,France

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: +41613241111
Email: novartis.email@novartis.com

Source URL: *https://prod1.novartis.com/clinicaltrials/study/nct06444087*

List of links present in page

1. https://clinicaltrials.gov/ct2/show/NCT06444087
2. #trial-eligibility
3. tel:+41613241111
4. mailto:novartis.email@novartis.com